Strategic Collaborations for Expanding Liquid Biopsy Use Globally

Explore strategic partnerships that are transforming liquid biopsy implementation in precision oncology through this 59-minute webinar featuring experts from SOPHiA GENETICS, AstraZeneca, and Synnovis. Discover how the collaboration between SOPHiA GENETICS and AstraZeneca is expanding global access to MSK-ACCESS® powered with SOPHiA DDM™ technology, addressing critical challenges in accuracy, scalability, and reproducibility of liquid biopsy testing. Learn about the technological and analytical foundations that enable non-invasive, real-time tumor genomic insights for more precise treatment decisions. Examine the strategic steps and real-world considerations involved in building a decentralized global testing network, including how clinical, regulatory, and infrastructural barriers are being addressed through collaborative approaches. Gain firsthand insights from Synnovis as an early adopter, including implementation experiences, successful strategies, and impacts on clinical research workflows. Understand how these partnerships are working to create more equitable access to cutting-edge cancer diagnostics worldwide, particularly in settings where liquid biopsy access has been limited, and explore the broader implications of such collaborations for advancing global cancer care.